We are live on ! Find out more
GANX icon

Gain Therapeutics
GANX

38 hedge funds and large institutions have $7.7M invested in Gain Therapeutics in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 4

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

9% more funds holding

Funds holding: 35 → 38 (+3)

0.57% less ownership

Funds ownership: 12.65% → 12.08% (-0.57%)

35% less capital invested

Capital invested by funds: $11.9M → $7.7M (-$4.15M)

Holders
38
Holders Change
+3
Holders Change %
+8.57%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
14
Reduced
4
Closed
6
Calls
$169K
Puts
–
Net Calls
+$169K
Net Calls Change
+$92K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$357K
2
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
+$235K
3
UBS Group
UBS Group
Switzerland
+$182K
4
Morgan Stanley
Morgan Stanley
New York
+$134K
5
Jane Street
Jane Street
New York
+$122K

Top Sellers

Rank Fund Capital Flow
1
GAM
Gotham Asset Management
New York
-$5.36M
2
Marshall Wace
Marshall Wace
United Kingdom
-$171K
3
DIG
Dauntless Investment Group
New Hampshire
-$82.8K
4
GCP
GSA Capital Partners
United Kingdom
-$23K
5
Northern Trust
Northern Trust
Illinois
-$19.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wealth Enhancement Advisory Services
26
Wealth Enhancement Advisory Services
Minnesota
$31.4K +$26.2K +15,556 New
Group One Trading
27
Group One Trading
Illinois
$29.7K +$17.5K +10,374 +162%
SCP
28
Sandhill Capital Partners
New York
$27.3K – – –
KAS
29
Kestra Advisory Services
Texas
$21.2K +$20.2K +12,000 New
HighTower Advisors
30
HighTower Advisors
Illinois
$20.5K +$19.5K +11,574 New
AA
31
Armis Advisers
Georgia
$19.8K – – –
NA
32
NewEdge Advisors
Louisiana
$18.8K – – –
CAM
33
Creekmur Asset Management
Illinois
$7.86K – – –
MCM
34
MAI Capital Management
Ohio
$7.81K – – –
Bank of America
35
Bank of America
North Carolina
$6.92K -$434 -257 -6%
AAP
36
Arax Advisory Partners
Colorado
$5.75K +$1.26K +750 +30%
Wells Fargo
37
Wells Fargo
California
$4.69K – – –
TRCT
38
Tower Research Capital (TRC)
New York
$3.65K +$1.89K +1,119 +118%
GAM
39
Gotham Asset Management
New York
– -$5.36M -245,896 Closed
DIG
40
Dauntless Investment Group
New Hampshire
– -$82.8K -46,000 Closed
GCP
41
GSA Capital Partners
United Kingdom
– -$23K -12,756 Closed
Simplex Trading
42
Simplex Trading
Illinois
– -$9.54K -5,657 Closed
Raymond James Financial
43
Raymond James Financial
Florida
– -$4.14K -2,300 Closed
SOW
44
State of Wyoming
Wyoming
– -$2.15K -1,194 Closed
1
2

GANX Hedge Fund Activity: Q3 2025 in Review

38 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q3 2025, worth a combined $7.7M — down 35% from $11.9M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new GANX positions and 6 closed out — a net gain of 3 holders — while 14 added to existing stakes and 4 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $357K. The largest seller was Gotham Asset Management, exiting entirely with an estimated $5.36M sold.

  • 38 institutional investors held Gain Therapeutics (GANX) as of Q3 2025, up from 35 in Q2 2025.
  • Funds reported $7.7M of Gain Therapeutics stock for Q3 2025, down 35% quarter-over-quarter.
  • 9 funds opened new Gain Therapeutics positions in Q3 2025 and 6 closed out, a net change of +3 holders.
  • The largest Gain Therapeutics buyer in Q3 2025 was Citadel Advisors, an estimated $357K added.
  • The largest Gain Therapeutics seller in Q3 2025 was Gotham Asset Management, an estimated $5.36M sold.

Based on aggregated 13F filings for Q3 2025.